February 9, 2004

For Immediate Release

Manufacturers Compete Hard for Market Opportunities in Application of Ablation and Other Energy-Based Therapeutic Technologies, According to Report from MedMarket Diligence

FOOTHILL RANCH, CA— Manufacturers of energy-based therapeutic technologies including cryogenic, radiofrequency, thermal, hydromechanical, laser, electrical, ultrasonic, microwave and radiation have developed sophisticated modalities to cut, cauterize, and ablate tissues with minimal invasiveness, little if any damage to surrounding tissues and high quality outcomes. The market for these diverse modalities exceeded $8 billion in the U.S in 2003, and select segments will grow in excess of 20% through 2013, according to a new report from MedMarket Diligence.

“Much of this market is characterized by aggressive competition as manufacturers have worked hard to develop their technologies to precisely match energy delivery with clinical application,” says Patrick Driscoll, President of MedMarket Diligence. According to Driscoll, a growing number of applications and patient caseload is coming from general, elective and orthopedic surgery, contributing to the already large and growing market for applications in cancer and cardiovascular disease.  “We have also seen much head-to-head competition by different modalities in a number of potential high growth applications, like endometrial ablation for treatment of menorrhagia and the alternatives for treatment of atrial arrhythmia, among others.”

The MedMarket Diligence report on Energy-Based Therapies (published February 2004) details the current and emerging application of energy-based technologies, with market size, growth through 2013 and competitor share assessments for clinical applications in cancer, atrial arrhythmia, bradycardia, vascular occlusive disease, ventricular arrhythmia, fecal incontinence, reflux disease, hysterectomy, menorrhagia, bladder neck suspension, urinary tract stones, BPH, and orthopedic applications (capsular shrinkage, carpal tunnel, chondroplasty, debridement, epicondylitis, tendinitis, inflammatory conditions and nucleoplasty).  Details on the report are available at http://www.mediligence.com/rpt-s110.htm.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  The company publishes the “MedMarkets” newsletter, a monthly analysis of the market implications of new medical technology and dedicated reports on technology markets.  For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit http://www.mediligence.com.